NewsBenzinga传奇生物报告：CARVYKTI单次注射后，CARTITUDE-2研究中50%的患者在5年后仍然保持无进展状态 传奇生物报告：CARVYKTI单次注射后，CARTITUDE-2研究中50%的患者在5年后仍然保持无进展状态 Benzinga 2026.09.25 11:03 (GMT+0) Open on Benzinga Other news BofA: US memory stock valuations show signs of cycle bottom, market concerns overblown BCX: Invest In Essential Resources, Collect 7% Monthly Income (NYSE:BCX) Tech stocks stumbled. Now comes a crucial week for Wall Street. UnitedHealth: My Thesis Has Played Out, I Wouldn't Chase Here (NYSE:UNH) OFG Bancorp: Risks Remain, But Not Enough To Prevent An Upgrade (NYSE:OFG) Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)
